| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Firestone Institute for Respiratory Health, and 6 Centre for Evaluation of Medicines, St. Joseph's Healthcare and McMaster University, Hamilton, 3 University of Waterloo, Waterloo, Ontario, 4 Unité de Recherche en Pneumologie, Institut de Cardiologie et de Pneumologie de l'Université Laval, Quebec City, and 5 Hôpital du Sacre-Coeur and University of Montreal, Montreal, Quebec, Canada, 2 NUPAIVA, Federal University of Santa Catarina, Florianópolis, Brazil.
CORRESPONDENCE: F. E. Hargreave, Firestone Institute for Respiratory Health, St. Joseph's Healthcare and McMaster University, 50 Charlton Avenue East, Hamilton, Ontario, Canada L8N 4A6. Fax: 1 9055216158. E-mail: hargreav{at}mcmaster.ca
Keywords: Asthma exacerbations, asthma treatment, induced sputum cell counts
Received: December 2, 2004
Accepted November 11, 2005
One important goal of asthma treatment is to reduce exacerbations. The current authors investigated if the use of sputum cell counts to guide treatment would achieve this goal.
A total of 117 adults with asthma were entered into a multicentre, randomised, parallel group-effectiveness study for two treatment strategies over a 2-yr period. In one strategy (the clinical strategy: CS) treatment was based on symptoms and spirometry. In the other (the sputum strategy: SS) sputum cell counts were used to guide corticosteroid therapy to keep eosinophils
The duration and number of exacerbations in Phase 1 were similar in both groups. In Phase 2 there were a 126 exacerbations of which 79 occurred in the CS (62.7%) and 47 (37.3%) in the SS groups. The majority of the 126 exacerbations (101; 80.1%) were mild. The majority of the 102 exacerbations, where sputum examination was performed before any treatment (n = 70), were noneosinophilic. In the SS patients, the time to the first exacerbation was longer (by 213 days) especially in those considered to need treatment with a long acting ß2-agonist (by 490 days), the relative risk ratio was lower (by 49%), and the number of exacerbations needing prednisone was reduced (5 versus 15). This benefit was seen mainly in patients needing treatment with inhaled steroid in a daily dose equivalent to fluticasone >250 µg, and was due to fewer eosinophilic exacerbations. The cumulative dose of corticosteroid during the trial was similar in both groups.
Monitoring sputum cell counts was found to benefit patients with moderate-to-severe asthma by reducing the number of eosinophilic exacerbations and by reducing the severity of both eosinophilic and noneosinophilic exacerbations without increasing the total corticosteroid dose. It had no influence on the frequency of noneosinophilic exacerbations, which were the most common exacerbations.
2%; symptoms and spirometry were used to identify clinical control, exacerbations and other treatments. Patients were blind to sputum cell counts in both strategies and physicians were blind in the CS, thus removing bias. First, the minimum treatment to maintain control was identified in 107 patients (Phase 1) and then this treatment was continued (Phase 2) for the remaining of the 2 yrs. The primary outcomes were the relative risk reduction for the occurrence of the first exacerbation in Phase 2 and the length of time without exacerbation. The current authors also examined the type and severity of exacerbations and the cumulative dose of inhaled steroid needed.
This article has been cited by other articles:
|
|
 |
|
  E. M. Erin, G. R. Jenkins, O. M. Kon, A. S. Zacharasiewicz, G. C. Nicholson, H. Neighbour, R. C. Tennant, A. J. Tan, B. R. Leaker, A. Bush, et al. Optimized Dialysis and Protease Inhibition of Sputum Dithiothreitol Supernatants Am. J. Respir. Crit. Care Med., January 15, 2008; 177(2): 132 - 141. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. H. Rowe and D. Vethanayagam The role of inhaled corticosteroids in the management of acute asthma Eur. Respir. J., December 1, 2007; 30(6): 1035 - 1037. [Full Text] [PDF]
|
|
|
|
|
|
P. M. O'Byrne The Demise of Anti IL-5 for Asthma, or Not Am. J. Respir. Crit. Care Med., December 1, 2007; 176(11): 1059 - 1060. [Full Text] [PDF]
|
|
|
|
 |
|
 P. G Gibson What do non-eosinophilic asthma and airway remodelling tell us about persistent asthma? Thorax, December 1, 2007; 62(12): 1034 - 1036. [Full Text] [PDF]
|
|
|
|
|
|
P. Flood-Page, C. Swenson, I. Faiferman, J. Matthews, M. Williams, L. Brannick, D. Robinson, S. Wenzel, W. Busse, T. T. Hansel, et al. A Study to Evaluate Safety and Efficacy of Mepolizumab in Patients with Moderate Persistent Asthma Am. J. Respir. Crit. Care Med., December 1, 2007; 176(11): 1062 - 1071. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L-P. Boulet and P. J. Sterk Airway remodelling: the future Eur. Respir. J., November 1, 2007; 30(5): 831 - 834. [Full Text] [PDF]
|
|
|
|
|
|
M. Nuijsink, W. C. J. Hop, P. J. Sterk, E. J. Duiverman, J. C. de Jongste, and on behalf of the Children Asthma Therapy Optimal ( Long-term asthma treatment guided by airway hyperresponsiveness in children: a randomised controlled trial Eur. Respir. J., September 1, 2007; 30(3): 457 - 466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Dolovich and D. P. Schuster Positron Emission Tomography and Computed Tomography versus Positron Emission Tomography Computed Tomography: Tools for Imaging the Lung Proceedings of the ATS, August 1, 2007; 4(4): 328 - 333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Taylor Exhaled NO: Forward, Backward, or Sideways? Am. J. Respir. Crit. Care Med., August 1, 2007; 176(3): 221 - 222. [Full Text] [PDF]
|
|
|
|
|
|
D. E. Shaw, M. A. Berry, M. Thomas, R. H. Green, C. E. Brightling, A. J. Wardlaw, and I. D. Pavord The Use of Exhaled Nitric Oxide to Guide Asthma Management: A Randomized Controlled Trial Am. J. Respir. Crit. Care Med., August 1, 2007; 176(3): 231 - 237. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Maneechotesuwan, S. Essilfie-Quaye, S. A. Kharitonov, I. M. Adcock, and P. J. Barnes Loss of Control of Asthma Following Inhaled Corticosteroid Withdrawal Is Associated With Increased Sputum Interleukin-8 and Neutrophils Chest, July 1, 2007; 132(1): 98 - 105. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L.-P. Boulet Review: inhaled corticosteroids reduce hospital admission and increase discharge rate during the first 4 hours in the emergency department for acute asthma Evid. Based Med., June 1, 2007; 12(3): 75 - 75. [Full Text] [PDF]
|
|
|
|
|
|
D. Menzies, A. Nair, and B. J. Lipworth Portable Exhaled Nitric Oxide Measurement: Comparison With the "Gold Standard" Technique Chest, February 1, 2007; 131(2): 410 - 414. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J M FitzGerald and P G Gibson Asthma exacerbations {middle dot} 4: Prevention. Thorax, November 1, 2006; 61(11): 992 - 999. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D R Taylor, M W Pijnenburg, A D Smith, and J C D Jongste Exhaled nitric oxide measurements: clinical application and interpretation. Thorax, September 1, 2006; 61(9): 817 - 827. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. E. Hargreave and K. Parameswaran Asthma, COPD and bronchitis are just components of airway disease. Eur. Respir. J., August 1, 2006; 28(2): 264 - 267. [Full Text] [PDF]
|
|
|
|
|
|
C. E. Brightling Clinical Applications of Induced Sputum Chest, May 1, 2006; 129(5): 1344 - 1348. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
